Asthma & Lung

This 6 month-long study aims to raise awareness of COVID-19 among Arizona populations disproportionately affected by the virus; Latino, American Indian, and African American communities. If you choose to participate, you will be asked to complete study questionnaires and receive information regarding prevention and treatment of COVID-19 by phone, handouts, text, or social media as well as be provided information regarding prevention and treatment trials that are available for COVID-19.

Primary disease category: 
Secondary disease category(ies): 

No study has been performed to prospectively record the presenting complaints, signs, symptoms and comorbidities of children who raised the suspicion of pulmonary embolism (PE). Clinicians must extrapolate what is known about PE in adults to children. Perhaps as a result, the mortality rate of PE is the same in children as it is in adults. On the other hand, tens of thousands of low risk children and adolescents are unnecessarily exposed to increased lifetime cancer risk from ionizing radiation from CT scans done to search for PE they do not have.

Primary disease category: 
Secondary disease category(ies): 

Adapt Out COVID is a study to evaluate the safety and efficacy of investigational agents for the treatment of non-hospitalized adults with COVID-19 symptoms. 

Primary disease category: 
Secondary disease category(ies): 

We will hold individual interviews of HLBS patients, including a range of racial, ethnic, and socioeconomic perspectives, to discuss current and future Artificial Intelligence/Big Data technologies. Participants will be recruited from University of Arizona affiliated clinical practices or online, offering $25 each for participation in 60-minute discussions, either by phone or video conference

Primary disease category: 
Secondary disease category(ies): 

A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.

 
Primary disease category: 
Secondary disease category(ies): 

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT)

Primary disease category: 

Your child is invited to participate because your child has a peanut allergy.  The study will last up to 72 weeks where you will take daily study drug, monthly study injections, complete study questionnaires/diaries, food challenge, skin prick tests, breathing tests, and have your blood drawn.

For Dupilumab there are common risks such as: conjunctivitis (pink eye), injection site reaction (swelling, redness, etc.), your child may experience a local or generalized allergic reaction (also known as a hypersensitivity reaction).

Primary disease category: 

This reseach is being done to evaluate the effectiveness of using Roflumilast as an alternative treatement of poorly controlled Asthma in obese patients.

Primary disease category: 
Secondary disease category(ies): 

A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.

Primary disease category: 

Pages

Subscribe to RSS - Asthma & Lung